This method is shown by semaglutide, which has a half-life that allows for once-weekly doses by changing amino acids and fatty acids in a smart way
GLP-1 receptor activation slows gastric emptying and alters gut signaling
Effects on: - Blood Sugar & Appetite: Minimal impact
cutoff = 24, Islam et al., 2023) and was excluded for that reason
Baseline bloodwork CBC, CRP, ferritin, IL-6, cortisol AM, metabolic panel, thyroid function Cardiovascular assessment heart rate variability, orthostatic vitals if POTS is suspected Gut health markers stool testing, zonulin, calprotectin if GI symptoms are prominent Mitochondrial function proxies lactate, organic acids panel if PEM is a primary complaint From there, a typical protocol might be structured as: Phase 1 (Weeks 16): Immune and gut foundation Thymosin Alpha-1: 1.6 mg subcutaneous, twice weekly BPC-157: 250500 mcg daily, route determined by predominant symptom (oral for gut, injectable for systemic) Phase 2 (Weeks 412): Tissue repair and cardiovascular recovery TB-500: 2.02.5 mg subcutaneous, twice weekly Continue BPC-157 as indicated Phase 3 (Weeks 816): Maintenance and metabolic support Taper or pulse doses based on clinical response Add mitochondrial support if fatigue persists (see: Mitochondrial Peptides and Insulin Resistance) These are illustrative dosing ranges based on clinical research and published protocols
[] This result agreed with the results obtained by a study in Moscow in which significantly low levels of total glutathione (tGSH) were recorded among 59 patients with COVID-19 with severe infections and a higher mortality rate
